Nexalin Technology (NXL) Projected to Release Quarterly Earnings on Wednesday

Nexalin Technology (NASDAQ:NXL) will likely be issuing its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect Nexalin Technology to announce earnings of ($0.10) per share and revenue of $0.09 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 7:00 AM ET.

Nexalin Technology (NASDAQ:NXL) last released its earnings results on Wednesday, August 12th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%.The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.09 million.

Nexalin Technology Stock Performance

Nexalin Technology stock opened at $0.25 on Monday. The company has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.41. Nexalin Technology has a 52 week low of $0.22 and a 52 week high of $2.00. The firm has a market capitalization of $5.62 million, a price-to-earnings ratio of -0.52 and a beta of 4.00.

Hedge Funds Weigh In On Nexalin Technology

A number of large investors have recently made changes to their positions in the business. PEAK6 LLC purchased a new stake in shares of Nexalin Technology in the fourth quarter worth approximately $266,000. Renaissance Technologies LLC grew its position in Nexalin Technology by 119.2% during the fourth quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock valued at $68,000 after purchasing an additional 66,400 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Nexalin Technology during the third quarter valued at approximately $57,000. Finally, Geode Capital Management LLC increased its stake in Nexalin Technology by 23.4% in the 4th quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock valued at $84,000 after buying an additional 28,454 shares during the period. Institutional investors and hedge funds own 0.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.